Revenues grew 28.7% YoY to | 3250 crore (I-direct estimate: | 3204 crore) mainly due to 66.7% rise in US sales to | 1642 crore (I-direct estimate: | 1464 crore) led by gLialda (ulcerative colitis) exclusivity & favourable seasonality impact on gTamiflu (anti-infective) EBITDA margins improved 870 bps to 25.8% (I-direct estimate: 25.0%), due to limited competition launches in the US. EBITDA increased 87.7% YoY to | 870 crore (I-direct estimate: | 801 crore) PAT increased 58% YoY to | 607 crore (I-direct estimate: | 496 crore)...